Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe

Research output: Contribution to journalReviewResearchpeer-review

  1. First patient with ILNEB syndrome due to pathogenic variants in ITGA3 surviving to adulthood

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A novel homoplasmic mt-tRNAGlu m.14701C>T variant presenting with a partially reversible infantile respiratory chain deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clinical manifestations and novel pathogenic variants in SOX10 in eight Danish probands with Waardenburg syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Phenotypic heterogeneity and mosaicism in Xia-Gibbs syndrome: Five Danish patients with novel variants in AHDC1

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Unique skeletal manifestations in patients with Primrose syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Recurrent Germline Variant in RAD21 Predisposes Children to Lymphoblastic Leukemia or Lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk of New Primary Cancer in Patients with Posterior Uveal Melanoma: A National Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Novel Genetic Causes of Gastrointestinal Polyposis Syndromes

    Research output: Contribution to journalReviewResearchpeer-review

  4. Danish guidelines for management of non-APC-associated hereditary polyposis syndromes

    Research output: Contribution to journalReviewResearchpeer-review

  • extended ERN-GENTURIS Thematic Group 3
  • Karin Wadt (Member of study group)
View graph of relations

Hereditary breast and ovarian cancer (HBOC) is a syndrome defined by an increased risk of developing breast and/or ovarian cancer most commonly due to germline disease-causing variants in the BRCA1 and BRCA2 genes, but also other causative genes such as PALB2, ATM and CHEK2. As genetic testing becomes more prevalent and new clinical data emerge, updates of national guidelines are required to incorporate these advances in our knowledge. The aim of this work is to review the guidelines for HBOC genetic testing and clinical surveillance across European countries, mostly affiliated to the European Reference Network (ERN) for Genetic Tumor Risk Syndroms (GENTURIS). Young onset breast cancer (BC), triple negative phenotype, or bilateral BC are considered as criteria for genetic testing in all, with differences in age limits. Testing of invasive epithelial non-mucinous ovarian cancer is also universally accepted. While breast magnetic resonance imaging (MRI) is consistently recommended in high-risk individuals, age of onset for mammograms differ between 30 and 40 years. Risk-reducing mastectomy is commonly offered as an option, while risk-reducing salpingo-oophorectomy is universally recommended. The largest differences are observed with respect to ovarian surveillance prior to risk-reducing salpingo-oophorectomy and in breast surveillance for carriers of non-BRCA1/2 genes. These differences in national guidelines reflect the variations in clinical consensus that may be reached in the absence of consistent evidence for some recommendations.

Original languageEnglish
Article number104350
JournalEuropean Journal of Medical Genetics
Volume64
Issue number12
Pages (from-to)104350
ISSN1769-7212
DOIs
Publication statusPublished - Dec 2021

Bibliographical note

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

    Research areas

  • BRCA1, BRCA2, Genetic testing, Guidelines, Hereditary breast ovarian cancer, Surveillance

ID: 73254587